MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.28 (-2.28%)

Company Metrics

  • P/E 13.83
  • P/S 10.20
  • P/B 2.51
  • EPS -1.53
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / N/A %
  • Avg. Vol. 575,594.00
  • Shares 68.60M
  • Market Cap. 821.79M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Oct 11, 2016
The 30-month stay that the Food and Drug Administration puts on generic drugs ends in February, but unless the patent dispute between Momenta/Novartis and Teva is resolved by then, the launch would be considered "at risk" because the duo would have to ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Boosted by Analyst Upgrade - Scibility Media
A Compelling Risk/Reward Seen In Momenta Pharmaceuticals - Benzinga
Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?
Motley Fool - Aug 9, 2016
While the report included sales of Momenta's and partner Novartis AG's (NYSE:NVS) Glatopa, the generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) once-daily Copaxone, investors should focus on the potential approval of the generic ...
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Momenta (MNTA) Collaborates with Mylan for 6 Biosimilars -
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals Inc. (MNTA) Cut to "Hold" at Zacks Investment Research
The Cerbat Gem - Oct 19, 2016
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
Momenta Pharmaceuticals (MNTA) Stock: Here's The What, Why & What's Next! - CNA Finance (press release)
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Latest Broker Views - NewsDen
Here's Why Maxim Downgraded Momenta Pharmaceuticals, Inc. (MNTA) to Sell
Smarter Analyst - Sep 7, 2016
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares are tumbling 4% today, with sales for its generic copaxone (glatopa), an injection designed to treat patients with relapsing and remitting forms of multiple sclerosis (RRMS), failing to impress or even ...
Analysts Downgrade of the Day: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Review Fortune
Momenta Pharmaceuticals Inc. (MNTA) Stock Rating Upgraded by Zacks Investment ...
The Cerbat Gem - Oct 13, 2016
Momenta Pharmaceuticals logo Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) target bumped up to $14.00 ... - Breaking Finance News
Today's Pattern Action: Momenta Pharmaceuticals, Inc. Could Help Your ...
Chester News - Oct 18, 2016
The stock of Momenta Pharmaceuticals, Inc. (MNTA) formed an up wedge with $20.14 target or 69.00% above today's $11.92 share price.
Stock Returns: Momenta Pharmaceuticals Inc (NASDAQ:MNTA) is Beating Aduro ... - CML News
ClariVest Asset Management LLC Acquires 4400 Shares of Momenta Pharmaceuticals ... - DailyQuint
Momenta Pharmaceuticals Inc. (MNTA) Downgraded by Zacks Investment Research to ...
Community Financial News - Oct 20, 2016
Momenta Pharmaceuticals Inc. logo Zacks Investment Research downgraded shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) from a buy rating to a hold rating in a report issued on Wednesday morning.
Momenta Pharmaceuticals Inc. (MNTA) shares fall following downgrade at Zacks ... - BNB Daily (blog)